Hospital admissions in individuals with HTLV-1 infection in Spain.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
20
2
2020
medline:
9
3
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital admissions. Retrospective, observational study using the Spanish National Hospital Discharge Database. Information for the diagnostic codes HTLV-1 and HTLV-2 using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was retrieved from the national public registry since 1997--2015. From a total of 66 462 136 nationwide hospital admissions recorded during the study period, 135 included HTLV diagnosis, being HTLV-1 in 115 (85.2%) and HTLV-2 in 20 (14.8%). The overall hospital admission rate because of HTLV was 2.03 per million, without significant yearly changes. First admissions represented 104 (77%) whereas 31 (23%) were re-admissions. The median in-hospital stay for HTLV patients was 9 days. In-hospital death occurred in 11 (8.1%). The median age of individuals with HTLV admission was 48 years and 60 (44.4%) were women. HTLV was recorded as the main diagnosis in 20%. The most frequent clinical conditions recorded alongside HTLV diagnosis were myelopathy (61; 45.2%), leukemia/lymphoma (30; 22.2%), solid organ transplantation (14; 10.4%) and child delivery (7; 5.2%). The rate of HTLV diagnosis in hospitalized patients in Spain is low, roughly of two per million admissions. Despite continuous large immigrant flows from HTLV-1 endemic areas, no significant rising in hospitalizations because of HTLV-1 associated illnesses were noticed during the last two decades. Classical clinical complications of HTLV-1 infection, such as myelopathy and lymphoma account for more than two-thirds of cases.
Identifiants
pubmed: 32073449
doi: 10.1097/QAD.0000000000002508
pii: 00002030-202006010-00006
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019-1027Références
Tagaya Y, Matsuoka M, Gallo R. 40 years of the HTLV: past, present, and future. F1000 Res 2019; 8: pii: F1000 Faculty Rev-228.
pii: f1000
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3:388.
Paiva A, Smid J, Haziot M, Assone T, Pinheiro S, Fonseca LAM, et al. High risk of heterosexual transmission of HTLV-1 infection in Brazil. J Med Virol 2017; 89:1287–1294.
Rosadas C, Taylor G. Mother-to-child HTLV-1 transmission: unmet research needs. Front Microbiol 2019; 10:999.
Murphy E. Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety. Transfus Clin Biol 2016; 23:13–19.
Bangham C, Araujo A, Yamano Y, Taylor G. HTLV-1 associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers 2015; 1:15012.
Phillips A, Harewood J. Adult T cell leukemia-lymphoma (ATL): state of the art. Curr Hematol Malig Rep 2018; 13:300–307.
Li H-C, Fujiyoshi T, Lou H, Yashiki S, Sonoda S, Cartier L, et al. The presence of ancient human T-cell lymphotropic virus type I provirus DNA in an Andean mummy. Nature Med 1999; 5:1428–1432.
Nishijima T, Shimada S, Noda H, Miyake K. Towards the elimination of HTLV-1 infection in Japan. Lancet Infect Dis 2019; 19:15–16.
Einsiedel L, Woodman R, Flynn M, Wilson K, Cassar O, Gessain A. HTLV-1 infection in an Indigenous Australian population: epidemiological insights from a hospital-based cohort study. BMC Public Health 2016; 15:787.
Soriano V, Tor J, Monzon M, Graus JM, Clotet B, Ribas-Mundo M. HTLV-1 in Spain. Lancet 1990; 336:627–628.
Treviño A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM. HTLV Spanish Study GroupTrends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. Virol J 2012; 9:71.
de Mendoza C, Caballero E, Aguilera A, Requena S, de Lejarazu RO, Pirón M, et al. Spanish HTLV NetworkHuman T-lymphotropic virus type 1 infection and disease in Spain. AIDS 2017; 31:1653–1663.
De Mendoza C, Pirón M, Gonzalez R, Jiménez A, Caballero E, Roc L, et al. HTLV Spanish Study GroupClinical presentation of individuals with HTLV-1 infection in Spain. Open Forum Infect Dis 2019; 6:ofz036.
Instituto Nacional de Gestión Sanitaria, Ministerio de Sanidad, Servicios Sociales e Igualdad. Spanish National Hospital Discharge Database. Conjunto Mínimo Básico de Datos, Hospitales del INSALUD. Available at: https://www.mscbs.gob.es/estadisticas/informe.do?numeracion=6. [Accessed 12 October 2019]
Ministerio de Sanidad, Servicios Sociales e Igualdad. Registro de altas de los hospitales generales del Sistema Nacional de Salud: CMBD. https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbd.htm. [Accessed 12 October 2019]
Estudio de las comorbilidades que componen el índice de Elixhauser. Análisis de prevalencia y fiabilidad en los registros del CMBD estatal de hospitalizacion. http://icmbd.es/docs/informe-comorbilidades-1.pdf. [Accessed 12 October 2019]
Ribera A, Marsal JR, Freira-González I, Cascant P, Pons JMV, Mitjavila F, Salas T, et al. Predicting in-hospital mortality with coronary by-pass surgery using hospital discharge data: comparison with a prospective observational study. Rev Esp Cardiol 2008; 61:843–852.
de Miguel-Díez J, López-de-Andrés A, Hernández-Barrera V, Jimenez-TrujilloF I, Mendez-Bailon M, de Miguel-Yanes JM, et al. Decreasing incidence and mortality among hospitalized patients suffering a ventilator-associated pneumonia: analysis of the Spanish national hospital discharge database from 2010 to 2014. Medicine (Baltimore) 2017; 96:e7625.
Herrador Z, Gherasim A, Jimenez B, Granados M, San Martín JV, Aparicio P. Epidemiological changes in leishmaniasis in Spain according to hospitalization-based records, 1997–2011: raising awareness towards leishmaniasis in non-HIV patients. PLoS Negl Trop Dis 2015; 9:e0003594.
INEbase/demography and population/population figures and demographic censuses/population figures. Available at: https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&cid=1254736176951&menu=resultados&idp=1254735572981. [Accessed 12 January 2012].
Toro C, Rodés B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003; 75:102–104.
Roc L, de Mendoza C, Fernández-Alonso M, Reina G, Soriano V. Spanish HTLV NetworkRapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals. Ther Adv Infect Dis 2019; 6:2049936119868028.
Pias-Peleteiro L, Pias-Peleteiro JM, Arias M. Tropical spastic paraparesis in a non tropical region. Rev Neurol 2015; 61:357–362.
de Mendoza C, Caballero E, Aguilera A, Benito R, Maciá D, García-Costa J, Soriano V, et al. Spanish HTLV NetworkHIV co-infection in HTLV-1 carriers in Spain. Virus Res 2019; 266:48–51.
Treviño A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, et al. HTLV infection in HCV-antibody positive patients in Spain. AIDS Res Hum Retroviruses 1013; 33:7.
Quiros-Roldan E, Moretti F, Torti C, Casari S, Castelli F, Beltrame A, Carosi G. HIV/HTLV co-infection: frequency and epidemiological characteristics among patients admitted to an Italian hospital. Infection 2003; 31:172–173.
Hjelle B, Appenzeller O, Mills R, Alexander S, Torres-Martinez N, Jahnke R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992; 339:645–646.
Martinez M, Al-Saleem J, Green P. Comparative virology of HTLV-1 and HTLV-2. Retrovirology 2019; 16:21.
Toro C, Aguilera A, Caballero E, Tuset C, Alvarez P, García-Campello M, et al. Hospital-based surveillance for HTLV-1/2 infections in Spain. AIDS Res Hum Retroviruses 2007; 23:1075–1077.
Treviño A, García J, de Mendoza C, Benito R, Aguilera A, de Lejarazu RO, et al. HTLV Spanish Study GroupPrevalence of HTLV-1/2 infections in Spain: a cross-sectional hospital-based survey. AIDS Res Hum Retroviruses 2010; 26:861–864.
Pérez-Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, et al. Cohorts of the Spanish AIDS Research Network (CoRIS and CoRIS-MD)Cohorts of the Spanish AIDS Research Network (CoRIS and CoRIS-MD). Clin Infect Dis 2009; 48:1467–1470.
Martinez-Perez A, Roure-Díez S, Belhassen-Garcia M, Torres-Tendero D, Perez-Arellano J, Cabezas T, et al. Soil-Transmitted Helminths’ Study Group of the Spanish Society of Tropical Medicine and International Health (SEMTSI)Management of severe strongyloidiasis attended at reference centers in Spain. PLoS Negl Trop Dis 2018; 12:e0006272.
Machuca A, Tuset C, Soriano V, Caballero E, Aguilera A, Ortiz de Lejarazu R. HTLV Spanish Study GroupSex Transm Infect 2000; 76:366–370.
Treviño A, Aguilera A, Caballero E, Toro C, Eiros JM, Ortiz de Lejarazu R, et al. Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain. AIDS Res Hum Retroviruses 2009; 25:551–554.
Ramos JM, Milla A, Treviño A, Sánchez V, Robledano C, Soriano V, Gutiérrez F. Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. J Clin Virol 2011; 51:192–194.
Treviño A, Benito R, Caballero E, Ramos JM, Parra P, Roc L, et al. HTLV infection among foreign pregnant women living in Spain. J Clin Virol 2011; 52:119–122.
Armstrong M, Corbett C, Rowe I, Taylor GP, Neuberger JM. HTLV-1 in solid organ transplantation: current challenges and future management strategies. Transplantation 2012; 94:1075–1084.
de Mendoza C, Roc L, Fernández-Alonso M, Soriano V. Spanish HTLV NetworkHTLV testing of solid organ transplant donors. Clin Transplant 2019; 18:e13670.
de Mendoza C, Roc L, Benito R, Reina G, Ramos JM, Gómez C, et al. Spanish HTLV NetworkHTLV-1 infection in solid organ transplant donors and recipients in Spain. BMC Infect Dis 2019; 19:706.
Adedayo O, Grell G, Bellot P. Hospital admissions for HTLV-1 associated diseases in Dominica. Postgrad Med J 2003; 79:341–344.
Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, et al. Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet J Rare Dis 2019; 14:227.
Shoeibi A, Rafatpanah H, Azarpazhooh A, Mokhber N, Hedayati-Moghaddam MR, Amiri A, et al. Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran. Acta Neurol Belg 2013; 113:427–433.